TNFα and TGFβ1 are highly upregulated in IPF and targeting profibrotic mediators induced downstream of TGFβ1 and TNFα represents a promising therapeutic approach for IPF2, 13. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.